世界最新医学信息文摘(连续型电子期刊)
世界最新醫學信息文摘(連續型電子期刊)
세계최신의학신식문적(련속형전자기간)
World Latest Medicine Information
2014年
32期
14-15
,共2页
瑞舒伐他汀%阿托伐他汀%冠心病
瑞舒伐他汀%阿託伐他汀%冠心病
서서벌타정%아탁벌타정%관심병
rosuvastatin%atorvastatin%coronary heart disease
目的:对比研究瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效。方法选取2012年8月至2013年8月我院诊治的冠心病患者130例,随机分为观察组和对照组,两组给予常规治疗,其中对照组口服阿托伐他汀钙,干预组口服瑞舒伐他汀钙,30天为一疗程。观察比较两组治疗后的效果。结果30天的治疗后,观察组的 tc、tG、ldl-c 以及 hs-crP 水平均有所降低,而 Hdl-c 水平以及 lVef 值有所升高,与对照组相比,差异具有统计学意义(P<0.05)。观察组总有效率为90.9%,对照组总有效率为80.8%,观察组总有效率显著高于对照组(P<0.05)。结论瑞舒伐他汀治疗冠心病患者的降脂疗效较好,且能改善心脏功能,较阿托伐他汀更具优势,值得临床上应用推广。
目的:對比研究瑞舒伐他汀與阿託伐他汀治療冠心病的療效。方法選取2012年8月至2013年8月我院診治的冠心病患者130例,隨機分為觀察組和對照組,兩組給予常規治療,其中對照組口服阿託伐他汀鈣,榦預組口服瑞舒伐他汀鈣,30天為一療程。觀察比較兩組治療後的效果。結果30天的治療後,觀察組的 tc、tG、ldl-c 以及 hs-crP 水平均有所降低,而 Hdl-c 水平以及 lVef 值有所升高,與對照組相比,差異具有統計學意義(P<0.05)。觀察組總有效率為90.9%,對照組總有效率為80.8%,觀察組總有效率顯著高于對照組(P<0.05)。結論瑞舒伐他汀治療冠心病患者的降脂療效較好,且能改善心髒功能,較阿託伐他汀更具優勢,值得臨床上應用推廣。
목적:대비연구서서벌타정여아탁벌타정치료관심병적료효。방법선취2012년8월지2013년8월아원진치적관심병환자130례,수궤분위관찰조화대조조,량조급여상규치료,기중대조조구복아탁벌타정개,간예조구복서서벌타정개,30천위일료정。관찰비교량조치료후적효과。결과30천적치료후,관찰조적 tc、tG、ldl-c 이급 hs-crP 수평균유소강저,이 Hdl-c 수평이급 lVef 치유소승고,여대조조상비,차이구유통계학의의(P<0.05)。관찰조총유효솔위90.9%,대조조총유효솔위80.8%,관찰조총유효솔현저고우대조조(P<0.05)。결론서서벌타정치료관심병환자적강지료효교호,차능개선심장공능,교아탁벌타정경구우세,치득림상상응용추엄。
Objective To observe and compare the efficacy of rosuvastatin and atorvastatin in the treatment of coronary heart disease. Methods 130 cases of patients with coronary heart disease were selected and divided into control group and observation group randomly. Both of the two group patients were treated with normal treatment. the observation group patients were treated with rosuvastatin and the control group patients were treated with atorvastatin. After 30 days, the treatment efficacy was observed. Results After the treatment of 30 days, the level of TC,TG,LDL-C and hs-CRP in observation group significantly decreased compared with control group, while the level of HDL-C and LVEF significantly increased compared with control group, with significant difference (P<0.05). the total effective rate of observation group was 93.85% and the control group was 80.00%, that in observation group was significantly higher than the control group(P<0.05). Conclusion rosuvastatin has a good effect on decreasing blood liquid level in patients with coronary heart disease, and it can improve cardiac function, which is better than atorvastatin. it is worthy popularizing.